Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jun 15, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to help doctors choose the best chemotherapy treatments for patients with colorectal cancer, which includes both colon and rectal cancer. Researchers want to compare the results of a special test that checks how cancer cells respond to different drugs in a lab setting (called a 3D drug sensitivity test) with how well patients do after treatment. The goal is to see if this test can help personalize treatment plans, making them more effective for each individual patient.

To participate in this study, you need to be between 18 and 75 years old and have been diagnosed with colorectal cancer. You should be planning to receive additional treatment after surgery and must have at least one tumor that can be tested. The study is currently recruiting participants, and if you join, you can expect to provide tumor samples for testing and to be closely monitored throughout the trial. This research aims to improve treatment options and outcomes for colorectal cancer patients, helping ensure that each person's treatment is tailored to their unique situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 \~ 75 years old, regardless of gender
• • Patients with colorectal cancer diagnosed by histopathology or cytology
• • Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
• • Having at least one assessable tumor focus
• • ECoG physical condition score ≤ 2 points
• • Voluntarily participate and sign informed consent
• Exclusion Criteria:
• • Patients diagnosed with metastasis
• • Patients who cannot obtain tumor samples
• • Pregnant and lactating women
• • Patients with poor compliance
• • Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment
• • Patients with other malignant tumors
• • Suffering from serious mental and nervous system diseases
• • The researchers believe that patients should not be selected for this study